Shares of Horizon Pharma Inc. (NASDAQ:HZNP) were down 1.1% on Tuesday . The stock traded as low as $22.20 and last traded at $22.30, with a volume of 1,872,390 shares trading hands. The stock had previously closed at $22.54.

Several analysts have recently weighed in on HZNP shares. Mizuho reaffirmed a “buy” rating and set a $25.00 price target (down previously from $34.00) on shares of Horizon Pharma in a research note on Tuesday, May 3rd. Guggenheim reaffirmed a “buy” rating on shares of Horizon Pharma in a research note on Tuesday, May 10th. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $34.00 price target (down previously from $44.00) on shares of Horizon Pharma in a research note on Tuesday, May 10th. Zacks Investment Research raised shares of Horizon Pharma from a “sell” rating to a “hold” rating in a research note on Wednesday, May 11th. Finally, TheStreet downgraded shares of Horizon Pharma from a “hold” rating to a “sell” rating in a research note on Tuesday, May 10th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $29.15.

The firm’s 50 day moving average price is $20.17 and its 200 day moving average price is $17.41. The company’s market cap is $3.60 billion.

Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.12. During the same period in the previous year, the business posted $0.39 EPS. The company had revenue of $257.40 million for the quarter, compared to analysts’ expectations of $235.43 million. The business’s revenue for the quarter was up 48.9% on a year-over-year basis. On average, equities research analysts predict that Horizon Pharma Inc. will post $2.15 EPS for the current fiscal year.

In related news, Director Virinder Nohria sold 25,000 shares of the stock in a transaction that occurred on Wednesday, June 15th. The shares were sold at an average price of $17.69, for a total transaction of $442,250.00. Following the completion of the transaction, the director now owns 189,836 shares of the company’s stock, valued at approximately $3,358,198.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jeffrey W. Sherman sold 2,900 shares of the stock in a transaction that occurred on Tuesday, August 2nd. The stock was sold at an average price of $20.00, for a total transaction of $58,000.00. The disclosure for this sale can be found here.

Other large investors have added to or reduced their stakes in the company. Airain ltd acquired a new stake in Horizon Pharma during the fourth quarter worth about $2,123,000. Morgan Stanley raised its stake in Horizon Pharma by 51.3% in the fourth quarter. Morgan Stanley now owns 548,234 shares of the biopharmaceutical company’s stock worth $11,881,000 after buying an additional 185,829 shares during the period. Finally, RS Investment Management Co. LLC raised its stake in Horizon Pharma by 59.8% in the fourth quarter. RS Investment Management Co. LLC now owns 2,210,448 shares of the biopharmaceutical company’s stock worth $47,900,000 after buying an additional 826,898 shares during the period.

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.